

Xiaonan Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3011275/publications.pdf>

Version: 2024-02-01

56
papers

2,796
citations

236925

25
h-index

189892

50
g-index

60
all docs

60
docs citations

60
times ranked

6247
citing authors

#	ARTICLE	IF	CITATIONS
1	In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma. <i>Diagnostic Pathology</i> , 2022, 17, 11.	2.0	4
2	Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	10
3	The role of hepatitis B virus surface proteins in regulating the maturation and secretion of complete and incomplete virions. <i>Journal of General Virology</i> , 2022, 103, .	2.9	3
4	Functional Comparison of Interferon α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon α and Interferon β Signaling. <i>Hepatology</i> , 2021, 73, 486-502.	7.3	51
5	Co-infection in COVID-19, a cohort study. <i>Journal of Infection</i> , 2021, 82, 414-451.	3.3	11
6	A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification. <i>Scientific Reports</i> , 2021, 11, 4405.	3.3	15
7	Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future. <i>Frontiers in Microbiology</i> , 2021, 12, 715450.	3.5	14
8	Probing the spatiotemporal patterns of HBV multiplication reveals novel features of its subcellular processes. <i>PLoS Pathogens</i> , 2021, 17, e1009838.	4.7	12
9	Evaluation of the in situ assay for HBV DNA. <i>Medicine (United States)</i> , 2021, 100, e27220.	1.0	3
10	ç³ç±³â”æµ«â”æšœœ~âœ”é†ç—†æ—°â†è,°ç,žæ,£è€...ç»šâ”æ,,ÿæÿ“è~šæ—ä,çš,,â”ç””. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Science B		
11	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. <i>Emerging Microbes and Infections</i> , 2020, 9, 1988-1996.	6.5	58
12	Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B. <i>Journal of Clinical Pathology</i> , 2020, 73, 813-818.	2.0	7
13	An integrated software for virus community sequencing data analysis. <i>BMC Genomics</i> , 2020, 21, 363.	2.8	5
14	A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia. <i>Antiviral Research</i> , 2020, 180, 104826.	4.1	9
15	Viral and host factors related to the clinical outcome of COVID-19. <i>Nature</i> , 2020, 583, 437-440.	27.8	746
16	An infectious clone of enterovirus 71(EV71) that is capable of infecting neonatal immune competent mice without adaptive mutations. <i>Emerging Microbes and Infections</i> , 2020, 9, 427-438.	6.5	9
17	Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection. <i>Discovery Medicine</i> , 2020, 29, 119-128.	0.5	0
18	A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts. <i>Cell Research</i> , 2019, 29, 696-710.	12.0	43

#	ARTICLE	IF	CITATIONS
19	Long-term functional maintenance of primary human hepatocytes in vitro. <i>Science</i> , 2019, 364, 399-402.	12.6	147
20	Visualization of Macrophage Lytic Cell Death During Mycobacterial Infection in Zebrafish Embryos via Intravital Microscopy. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	7
21	Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. <i>Antiviral Research</i> , 2018, 152, 45-52.	4.1	16
22	Differentially Expressed Intrahepatic Genes Contribute to Control of Hepatitis B Virus Replication in the Inactive Carrier Phase. <i>Journal of Infectious Diseases</i> , 2018, 217, 1044-1054.	4.0	30
23	Extracellular Hepatitis B Virus RNAs Are Heterogeneous in Length and Circulate as Capsid-Antibody Complexes in Addition to Virions in Chronic Hepatitis B Patients. <i>Journal of Virology</i> , 2018, 92, .	3.4	45
24	Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. <i>International Journal of STD and AIDS</i> , 2017, 28, 380-388.	1.1	6
25	PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. <i>Hepatology</i> , 2017, 66, 398-415.	7.3	101
26	Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line. <i>Molecular and Cellular Proteomics</i> , 2017, 16, S144-S160.	3.8	56
27	Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. <i>Scientific Reports</i> , 2017, 7, 43446.	3.3	68
28	Predictive model for inflammation grades of chronic hepatitis B: Large-scale analysis of clinical parameters and gene expressions. <i>Liver International</i> , 2017, 37, 1632-1641.	3.9	62
29	Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. <i>Scientific Reports</i> , 2017, 7, 15658.	3.3	14
30	Establishment of a fluorescent in situ hybridization assay for imaging hepatitis B virus nucleic acids in cell culture models. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-6.	6.5	6
31	Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B. <i>BMC Gastroenterology</i> , 2017, 17, 140.	2.0	12
32	In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. <i>Journal of Clinical Investigation</i> , 2016, 126, 1079-1092.	8.2	83
33	MicroRNA-939 restricts Hepatitis B virus by targeting Jmjd3-mediated and C/EBPβ-coordinated chromatin remodeling. <i>Scientific Reports</i> , 2016, 6, 35974.	3.3	19
34	The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor. <i>Chemical Communications</i> , 2016, 52, 3340-3343.	4.1	9
35	A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles. <i>Medicine (United States)</i> , 2016, 95, e2511.	1.0	3
36	Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. <i>Scientific Reports</i> , 2015, 5, 16459.	3.3	49

#	ARTICLE	IF	CITATIONS
37	Extra-pulmonary viral shedding in H7N9 Avian Influenza patients. <i>Journal of Clinical Virology</i> , 2015, 69, 30-32.	3.1	28
38	Genetic and phenotypic characterization of <i>Candida albicans</i> strains isolated from infectious disease patients in Shanghai. <i>Journal of Medical Microbiology</i> , 2015, 64, 74-83.	1.8	24
39	Oral Administered Particulate Yeast-Derived Glucan Promotes Hepatitis B Virus Clearance in a Hydrodynamic Injection Mouse Model. <i>PLoS ONE</i> , 2015, 10, e0123559.	2.5	10
40	PCR for Detection of Oseltamivir Resistance Mutation in Influenza A(H7N9) Virus. <i>Emerging Infectious Diseases</i> , 2014, 20, 847-849.	4.3	10
41	Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-9.	6.5	32
42	Comparison of Circulating, Hepatocyte Specific Messenger RNA and microRNA as Biomarkers for Chronic Hepatitis B and C. <i>PLoS ONE</i> , 2014, 9, e92112.	2.5	30
43	Hepatitis B virus polymerase impairs interferon- λ -induced STAT activation through inhibition of importin- λ 5 and protein kinase C- ζ . <i>Hepatology</i> , 2013, 57, 470-482.	7.3	99
44	Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: Evaluation of antiviral efficacy in a murine infection model. <i>Antiviral Research</i> , 2013, 97, 264-269.	4.1	79
45	Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. <i>Lancet, The</i> , 2013, 381, 2273-2279.	13.7	308
46	Infection of inbred BALB/c and C57BL/6 and outbred Institute of Cancer Research mice with the emerging H7N9 avian influenza virus. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	6.5	14
47	Plasma Microrna Profile as a Predictor of Early Virological Response to Interferon Treatment in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2012, 17, 1243-1253.	1.0	33
48	Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. <i>Journal of General Virology</i> , 2009, 90, 2686-2694.	2.9	41
49	A random PCR screening system for the identification of type 1 human herpes simplex virus. <i>Journal of Virological Methods</i> , 2009, 161, 91-97.	2.1	3
50	Whole recombinant <i>Hansenula polymorpha</i> expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses. <i>Vaccine</i> , 2009, 28, 187-194.	3.8	28
51	Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. <i>Clinical Immunology</i> , 2008, 128, 400-408.	3.2	134
52	Computational analyses of JAK1 kinase domain: Subtle changes in the catalytic cleft influence inhibitor specificity. <i>Biochemical and Biophysical Research Communications</i> , 2008, 370, 72-76.	2.1	10
53	Desflurane Preconditioning Inhibits Endothelial Nuclear Factor- κ B Activation by Targeting the Proximal End of Tumor Necrosis Factor- α Signaling. <i>Anesthesia and Analgesia</i> , 2008, 106, 1473-1479.	2.2	14
54	Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. <i>Journal of General Virology</i> , 2007, 88, 3260-3269.	2.9	81

#	ARTICLE	IF	CITATIONS
55	Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Letters, 2006, 580, 4392-4400.	2.8	58
56	Direct interaction between β -actinin and hepatitis C virus NS5B. FEBS Letters, 2003, 554, 289-294.	2.8	25